INVENTAGE LAB, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,330 KRW | +0.39% |
|
+5.95% | -40.63% |
More news
| 1 day | +0.39% | ||
| 1 week | +5.95% | ||
| Current month | +2.68% | ||
| 1 month | +5.19% | ||
| 3 months | -18.21% | ||
| 6 months | -32.44% | ||
| Current year | -40.63% |
1 week
9 450.00
11 300.00
1 month
9 450.0013 390.00
Current year
9 400.0021 400.00
1 year
8 800.0032 750.00
3 years
8 440.0032 750.00
5 years
8 440.0032 750.00
10 years
8 440.0032 750.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ju-Hee Kim
CEO | Chief Executive Officer | - | 13/05/15 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 25/06/24 | 10,680 | +3.39% | 522,735 |
| 24/06/24 | 10,330 | +0.39% | 64,521 |
| 21/06/24 | 10,290 | -3.56% | 154,972 |
| 20/06/24 | 10,670 | +3.69% | 207,236 |
| 19/06/24 | 10,290 | +7.08% | 352,945 |
End-of-day quote Korea S.E., June 23, 2024
More quotes
Inventage Lab Inc is a Korea-based company principally engaged in the pharmaceutical business. The Company owns the platforms applied to the development and mass production of long-acting injections and drug delivery of genetic materials. The Company is engaged in the research, manufacture and sale of human medicines used for male pattern baldness, dementia, prostate cancer and others. It is also engaged in the research, manufacture and sale of veterinary medicines such as combination drugs, chemical castration agents and others.
Sector
Pharmaceuticals
Calendar
11/08/2024
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -40.63% | 62.99M | |
| +55.19% | 801B | |
| +47.26% | 631B | |
| -6.09% | 359B | |
| +21.92% | 337B | |
| +18.40% | 245B | |
| +3.64% | 231B | |
| +12.98% | 219B | |
| +10.86% | 171B | |
| -2.78% | 161B |
- Stock Market
- Equities
- A389470 Stock
